Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Omar Nadeem; Michelle P. Aranha; Robert Redd; Michael Timonian; Sophie Magidson; Elizabeth D. Lightbody; Jean-Baptiste Alberge; Luca Bertamini; Ankit K. Dutta; Habib El-Khoury; Mark Bustoros; Jacob P. Laubach; Giada Bianchi; Elizabeth O’Donnell; Ting Wu; Junko Tsuji; Kenneth Anderson; Gad Getz; Lorenzo Trippa; Paul G. Richardson; Romanos Sklavenitis-Pistofidis; Irene M. Ghobrial

doi:10.1101/2024.04.19.24306082

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Omar Nadeem, Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody, Jean-Baptiste Alberge, Luca Bertamini, Ankit K. Dutta, Habib El-Khoury, Mark Bustoros, Jacob P. Laubach, Giada Bianchi, Elizabeth O’Donnell, Ting Wu, Junko Tsuji, Kenneth Anderson, Gad Getz, Lorenzo Trippa, Paul G. Richardson, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial

doi: https://doi.org/10.1101/2024.04.19.24306082

Omar Nadeem

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: irene_ghobrial{at}dfci.harvard.edu omar_nadeem{at}dfci.harvard.edu

Michelle P. Aranha

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert Redd

2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Timonian

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sophie Magidson

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elizabeth D. Lightbody

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean-Baptiste Alberge

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Luca Bertamini

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ankit K. Dutta

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Habib El-Khoury

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark Bustoros

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

3Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, New York, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacob P. Laubach

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Giada Bianchi

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elizabeth O’Donnell

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ting Wu

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Junko Tsuji

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kenneth Anderson

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gad Getz

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lorenzo Trippa

2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul G. Richardson

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Romanos Sklavenitis-Pistofidis

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4Broad Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Irene M. Ghobrial

1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: irene_ghobrial{at}dfci.harvard.edu omar_nadeem{at}dfci.harvard.edu

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Data availability

Single-cell RNA and TCR-sequencing raw data generated for this study will be deposited in dbGaP (study site pending). Gene expression matrices can be accessed on Mendeley: https://data.mendeley.com/preview/z56k3y8cdg?a=6945f72a-b190-4fb1-b0fe-31c12a70a0d4 (reserved DOI:10.17632/z56k3y8cdg.1)

View the discussion thread.

PreviousNext

Posted April 19, 2024.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone